Capricor Therapeutics Announces Late-Breaking Presentations

-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy--C...

Related Keywords

South Carolina , United States , Japan , Charleston , Joyce Allaire , Linda Marb , Raquel Cona , Capricor Stealth , Instagram , Capricor Therapeutics Inc , Ns Pharma Inc , World Muscle Society , Twitter , International Annual Congress , Exchange Commission On , Nippon Shinyaku Co Ltd , Lifesci Advisors , Nasdaq , Capricor Company Contact , Facebook , Company Stealth , Technology Shows Promise Of Exosome , Strategic Communications , Month Open Label Extension Data , Treating Duchenne Muscular , Technology Shows Promise , Exosome Based Delivery , Breaking Poster , Term Safety , Upper Limb , Enhanced Exosome Based , Chief Executive , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Quarterly Report , Investigational New Drug , Media Contact , Investor Contact , Sci Advisors , Company Contact , Chief Financial ,